Efficacy of venovenous extracorporeal membrane oxygenation for neonates with respiratory and circulatory compromise.
We report a 12-month experience at Egleston Children's Hospital in Atlanta, Ga., with a protocol under which venovenous extracorporeal membrane oxygenation (ECMO) was used instead of venoarterial ECMO. Fifty-five newborn infants were referred for ECMO, four of whom had disqualifying conditions (all four died). Thirty-one infants were supported without recourse to ECMO, one of whom died. Of the 20 remaining patients, three were placed on a venoarterial ECMO regimen because of our early uncertainty about the efficacy of venovenous ECMO or because of technical constraints. All other patients (n = 17), including three with congenital diaphragmatic hernia, were supported with venovenous perfusion. No patient begun on a venovenous ECMO regimen required conversion to venoarterial bypass. Before ECMO, venovenous patients required an average dopamine dose of 16 micrograms/kg per minute and an average dobutamine dose of 6 micrograms/kg per minute. Of 15 patients studied before ECMO, three had significantly impaired contractility, and all had evidence of pulmonary hypertension on an echocardiogram. Mean blood pressure did not change while heart rate fell from 172 to 146 beats/min during the first 2 hours of ECMO and vasoactive drug doses were reduced. Of the 17 venovenous ECMO patients, 15 (88%) survived. We conclude that neonatal patients with severe hypoxia and substantial circulatory compromise can be effectively supported by venovenous ECMO in most cases.
Cornish
J D
JD
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Heiss
K F
KF
Clark
R H
RH
Strieper
M J
MJ
Boecler
B
B
Kesser
K
K
D001775:Blood Circulation; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D015199:Extracorporeal Membrane Oxygenation / Q000379:methods*; D005260:Female; D006325:Heart Atria; D006331:Heart Diseases / Q000628:therapy*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011667:Pulmonary Veins; D012131:Respiratory Insufficiency / Q000628:therapy*; D015996:Survival Rate; D013997:Time Factors
D004280:Dobutamine; D004298:Dopamine